DESCRIPTION:

This talk explores the toxicity and tolerability challenges in hormone-receptor positive breast cancer, with a focus on novel approaches to improving endocrine therapy side effects and new investigator-initiated trial concepts.

LEARNING OBJECTIVES

• Understand the therapeutic burden of endocrine therapy in early-stage HR+ breast cancer, including rates of treatment discontinuation, common toxicities, and their impact on recurrence risk.
• Evaluate the role of chronotherapy in improving treatment tolerability and adherence by aligning endocrine therapy with circadian rhythms, supported by emerging clinical and pilot study data.
• Identify future directions in symptom science and supportive care research, including pilot interventional trials targeting circadian disruption, therapy-induced alopecia, and targeted therapy–related metabolic toxicities.